Journal
OPHTHALMIC GENETICS
Volume 39, Issue 5, Pages 560-568Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/13816810.2018.1495745
Keywords
Adeno-associated virus; gene therapy; inherited retinal diseases
Categories
Funding
- National Institute of Health [5P30EY019007, R01EY018213, R01EY024698, R01EY026682, R21AG050437]
- National Cancer Institute Core [5P30CA013696]
- Research to Prevent Blindness (RPB) Physician-Scientist Award
- RPB, New York, NY, USA
- Tistou and Charlotte Kerstan Foundation
- Schneeweiss Stem Cell Fund, New York State [C029572]
- Foundation Fighting Blindness New York Regional Research Center Grant [C-NY05-0705-0312]
- Crowley Family Fund
- Gebroe Family Foundation
Ask authors/readers for more resources
Hereditary diseases of the retina represent a group of diseases with several heterogeneous mutations that have the common end result of progressive photoreceptor death leading to blindness. Retinal degenerations encompass multifactorial diseases such as age-related macular degeneration, Leber congenital amaurosis, Stargardt disease, and retinitis pigmentosa. Although there is currently no cure for degenerative retinal diseases, ophthalmology has been at the forefront of the development of gene therapy, which offers hope for the treatment of these conditions. This article will explore an overview of the clinical trials of gene supplementation therapy for retinal diseases that are underway or planned for the near future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available